2. Academic Validation
  3. Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition

Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition

  • Oncoimmunology. 2023 Mar 30;12(1):2197360. doi: 10.1080/2162402X.2023.2197360.
Laura Codarri Deak 1,  Masao Hashimoto 2,  Pablo Umaña 1,  Christian Klein 1
Affiliations

Affiliations

  • 1 Roche Innovation Center Zurich, Cancer Immunotherapy Discovery, Roche Pharma Research and Early Development, Schlieren, Switzerland.
  • 2 Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.
PMID: 37025392 DOI: 10.1080/2162402X.2023.2197360
Abstract

The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1+ T-cells and acts on antigen-specific stem-like PD-1+ TCF-1+ CD8+ T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic Infection and tumor models compared to checkpoint inhibition.

Keywords

Eciskafusp alfa; IL-2; PD-1; PD1-IL2v; RG6279; TCF-1.

Figures
Products